Gene expression tests for women with early stage breast cancer a review of clinical utility and cost-effectiveness
While each gene expression test has been independently clinically validated using prospective or retrospective evidence, currently, there is no gold-standard for breast cancer gene expression tests. This highlights the need for comparative assessments of clinical utility and cost-effectiveness
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
October 16, 2017, 2017
|
| Edition: | Version 1.0 |
| Series: | Rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | While each gene expression test has been independently clinically validated using prospective or retrospective evidence, currently, there is no gold-standard for breast cancer gene expression tests. This highlights the need for comparative assessments of clinical utility and cost-effectiveness |
|---|---|
| Physical Description: | 1 PDF file (14 pages) illustrations |